SCYNEXIS, Inc. — Company profile
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 3.76 USD (Oct 30, 2026, 1:55 PM EDT) · Market cap 37.41M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Details
| Name | SCYNEXIS, Inc. |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Employees | 18 |
| Founded | 1999 |
| Ipo Date | 2014-05-02 |
| Ceo | David Angulo |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US8112923094 |
| Cusip | 811292309 |
| Cik | 0001178253 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. David Gonzalez Angulo M.D. | Chief Executive Officer, President and Director |
| Scott Sukenick J.D. | Chief Legal Officer and Corporate Secretary |
Contact
| Address | 1 Evertrust Plaza, 13th Floor, Jersey City, New Jersey 07302-6548, United States |
| Phone | 201 884 5485 |
| Website | https://www.scynexis.com |